Earnings Call Intelligence Subscribe
Home › Call Sheets › BIIB › Q1'26
Call sheet · Q1'26

Biogen (BIIB)

Q1'26 earnings call · held April 29, 2026 · compared with the Q4'25 call · management-credibility review
11/12
Disclosure score
4 medium, 2 low flags
Financial quality
Bottom line
The real story everyone's missing is that Apellis isn't just about geographic atrophy - it's about buying an immediate nephrology commercial presence for the felzartamab launch in 2027. Viehbacher explicitly said this gives them 'presence in nephrology offices now with a marketed product, not a future product.' While the Street obsesses over SYFOVRE's competitive dynamics, Biogen is building relationships with the exact physicians who'll prescribe their $2-3B AMR opportunity. The binding constraint isn't pipeline execution anymore - it's commercial infrastructure in new therapeutic areas, which this acquisition directly addresses. As Viehbacher noted: 'within Biogen, I think we can probably bring more resources to really support those teams.' My view changes if the Apellis integration costs exceed $200M annually or if BIIB080 tau data shows <30% tau reduction - both would signal execution problems ahead of the 2027-2028 launch wave.

The 30-second version

  • The REAL story: Apellis acquisition creates immediate nephrology beachhead while everyone obsesses over GA
  • Growth products hit $850M (+12% YoY) but SPINRAZA timing games mask underlying strength
  • Guidance shenanigans: $145M of 'acquired IP R&D charges' in Q2 conveniently obscures operating performance

What changed this quarter

MetricQ4'25Q1'26Change
Total Revenue$2.5B (Q4)$2.5B (Q1)Flat sequentially, +2% YoY
Growth Products Revenue$850M (Q4)$851M (Q1)+12% YoY acceleration
GAAP Diluted EPS$1.99 (Q4)$2.15 (Q1)+31% YoY surge
Non-GAAP Diluted EPS$15.28 (FY25)$3.57 (Q1)+18% YoY
LEQEMBI Revenue$134M (Q4)$168M (Q1)+74% YoY, +25% sequential
SKYCLARYS Revenue$133M (Q4)$151M (Q1)+22% YoY despite inventory headwinds
Free Cash Flow$2.1B (FY25)$594M (Q1)Strong quarterly generation
Non-GAAP R&D ExpenseNot specified Q4$480M (Q1)YoY increase from Phase III investments
Non-GAAP SG&A ExpenseNot specified Q4$600M (Q1)YoY increase from prelaunch activities
Cash and Marketable Securities$4.2B (Q4)$4.7B (Q1)+$500M buildup pre-Apellis

Accountability tracked

8 new promises made3 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full BIIB Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.